S&P Futures
4,088.50 +7.25 (+0.18%) Dow Futures
34,612.00 +13.00 (+0.04%) Nasdaq Futures
12,062.25 +20.00 (+0.17%) Russell 2000 Futures
1,893.60 +6.10 (+0.32%) Crude Oil
80.89 +0.34 (+0.42%) Gold
1,790.20 +30.30 (+1.72%)
RVL PHARMACEUT. DL-,01 (O1P.MU)
Chart Events
Performance Outlook
| Previous Close | 1.4000 |
| Open | 1.4000 |
| Bid | 1.3200 x N/A |
| Ask | 1.4300 x N/A |
| Day's Range | 1.4000 - 1.4000 |
| 52 Week Range | 0.9500 - 2.9400 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks Small Cap Research
RVLP: Can’t Take My Eyes Off You
By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT We are initiating coverage of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share. RVL’s lead and only marketed asset is Upneeq®, a product developed to treat acquired blepharoptosis, or low-lying eyelids. Following approval for Upneeq in July 2020, RVL embarked on a structured commercialization effort
- GlobeNewswire
RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update
-- Third quarter 2022 UPNEEQ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022 -- -- Anticipates fourth quarter 2022 UPNEEQ net product sales to grow approximately 20% - 40% over the third quarter 2022, representing sales of approximately $12 - $14 million
- GlobeNewswire
RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Commercial Update
-- Conference call to be held Thursday, November 10, 2022, at 4:30 p.m. ET --BRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its third quarter 2022 financial results and provide a commercial update on Thursday, November 10, 2022, after the close of
